ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC) - Rittmeyer, A; Solomon, B; Ahn, JS; Barlesi, F; Dziadziuszko, R; Nishio, M; Shaw, A; Bordogna, W; Meyenberg, C; Wu, YL (Pneumologie, 2020)